In the NCI-sponsored Prostate Cancer Prevention Trial (PCPT), initial findings from a decade ago showed that the drug finasteride significantly reduced the risk of prostate cancer, but among those who did develop prostate cancer, paradoxically, the drug was associated with an increased risk of high-grade disease.
A study published in the May 2008 issue of the peer-reviewed Journal of Urology demonstrates that the prostate cancer gene 3 (PCA3) can be used to detect and stratify stage and grade of prostate cancer.
Researchers have found that gene expression changes in prostate tissue surrounding cancer lesions may allow diagnosis of prostate cancer even if no cancer cells are present in biopsy tissue, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.
New research, to be published in the Journal of Clinical Psychiatry, finds that men who developed persistent sexual side effects while on finasteride (Propecia), a drug commonly used for male pattern hair loss, have a high prevalence of depressive symptoms and suicidal thoughts.
Researcher Michael S. Irwig, M.D., F.A.C.E., assistant professor of medicine at the George Washington University School of Medicine and Health Sciences and director of the Center for Andrology at The GW Medical Faculty Associates, found that men who used the medication finasteride (Propecia) and developed persistent sexual side effects, are also drinking less alcohol than before.
Finasteride, a medication approved to treat hair loss in men, may also improve the condition in women when combined with oral contraceptives, according to an article in the March issue of Archives of Dermatology.
Molecular dermatology research and development innovator HairDX today announced the results of a six month pilot study that presents, for the first time, evidence that genetic mechanisms may predict treatment response to Finasteride for postmenopausal female Androgenetic Alopecia (female hair loss).
Men with prostate cancer and their partners face difficult decisions regarding treatment, and accurate information regarding expected outcomes can be hard to find, according to results of a multi-center study published Wednesday in the New England Journal of Medicine.